8315

BI-Lilly Alliance Creates Formidable Drug Development Combine

Pharma giants Boehringer Ingelheim (BI) and Eli Lilly and Company (Lilly) have formed the

BI-Lilly Diabetes Alliance, a joint effort, involving the development of several drugs aimed at treating type 1 and type 2 diabetes patients.

The Alliance recently showed up in force at the 74th American Diabetes Association Scientific Sessions in San Francisco, June 13-17. It made more than 40 presentations on drugs and drug combinations now under development, including:

The presentation of six clinical abstracts for an investigational basal insulin, LY2963016, a new insulin glargine product. It is being developed for the treatment of both type 1 and type 2 patients.

The Alliance presented 17 clinical and non-clinical abstracts on the investigational compound empagliflozin; a sodium glucose cotransporter-2 (SGLT2) inhibitor under study as a blood glucose reducer in type 2 adults. Like other drugs in this fairly new class, empagliflozin blocks glucose reabsorption in the kidney by shunting some of it to the urinary tract.

Two late-breaker abstracts discussed an investigational combination empagliflozin and linagliptin (marketed in the United States as Tradjenta®) for the type 2s. Linagliptin is a DPP-4 inhibitor, which works by blocking the enzyme dipeptidyl peptidase IV. The enzyme destroys proteins that stimulate insulin-producing cells, so by inhibiting its action, linagliptin allows for greater insulin production and slows gastric emptying.

Combining the two drugs in one tablet marks the first time that a DPP-4 inhibitor and an SGLT-2 inhibitor have been brought together as a distinct type 2 therapy.

The Alliance also presented information on Jentadueto®, a linagliptin/metformin combination used to treat type 2s (it is noBI-Lilly Alliance Creates Formidable Drug Development Combine

Diabetes Health Staff

Pharma giants Boehringer Ingelheim (BI) and Eli Lilly and Company (Lilly) have formed the

BI-Lilly Diabetes Alliance, a joint effort, involving the development of several drugs aimed at treating type 1 and type 2 diabetes patients.

The Alliance recently showed up in force at the 74th American Diabetes Association Scientific Sessions in San Francisco, June 13-17. It made more than 40 presentations on drugs and drug combinations now under development, including:

The presentation of six clinical abstracts for an investigational basal insulin, LY2963016, a new insulin glargine product. It is being developed for the treatment of both type 1 and type 2 patients.

The Alliance presented 17 clinical and non-clinical abstracts on the investigational compound empagliflozin; a sodium glucose cotransporter-2 (SGLT2) inhibitor under study as a blood glucose reducer in type 2 adults. Like other drugs in this fairly new class, empagliflozin blocks glucose reabsorption in the kidney by shunting some of it to the urinary tract.

Two late-breaker abstracts discussed an investigational combination empagliflozin and linagliptin (marketed in the United States as Tradjenta®) for the type 2s. Linagliptin is a DPP-4 inhibitor, which works by blocking the enzyme dipeptidyl peptidase IV. The enzyme destroys proteins that stimulate insulin-producing cells, so by inhibiting its action, linagliptin allows for greater insulin production and slows gastric emptying.

Combining the two drugs in one tablet marks the first time that a DPP-4 inhibitor and an SGLT-2 inhibitor have been brought together as a distinct type 2 therapy.

The Alliance also presented information on Jentadueto®, a linagliptin/metformin combination used to treat type 2s (it is not used with type 1 patients) currently being marketed in the United States.

t used with type 1 patients) currently being marketed in the United States.

Leave a Reply

Your email address will not be published. Required fields are marked *


Time limit is exhausted. Please reload CAPTCHA.